GLP-1 and Iris Function for Improved Calorie Balance: A Targeted Synthesis
Despite the significant advancements in the field of obesity management, the search for effective therapies remains an active area of research. One such therapy that has garnered attention is the use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for the treatment of obesity and type 2 diabetes. In this article, we provide a targeted synthesis of recent developments in the field of GLP-1 neurobiology, highlighting studies that have advanced our understanding of how GLP-1 signaling modulates eating, and identify open questions and future challenges that need to be addressed to aid the prevention and/or treatment of obesity.
Modulation of Eating and Energy Balance
Centrally, GLP-1RAs modulate brain regions controlling appetite, influencing neurotransmitter and peptide release to regulate hunger and energy expenditure. GLP-1RAs have been shown to reduce food intake, increase feelings of fullness, and improve glucose homeostasis. Further, these agents have been linked to improved insulin sensitivity and increased pancreatic insulin secretion.
GLP-1 Signaling Pathways
GLP-1 signaling pathways are complex and involve multiple cellular and molecular mechanisms. Central GLP-1 binds to GLP-1 receptor (GLP-1R) to exert various effects, including modulation of energy balance, cardiovascular function, learning and memory, rewarding effect of food, and thermogenesis. Peripheral GLP-1 serves as an incretin hormone, increasing postprandial insulin secretion and reducing glucagon levels.
Natural Alternatives to GLP-1 RAs
Although GLP-1RAs have shown promise in the management of obesity and type 2 diabetes, their administration does pose challenges. For example, managing side effects such as nausea and vomiting, and and adherence to injectable treatments. There is growing interest in natural compounds that can modulate GLP-1 signaling. These agents, such as butyrate, a short-chain fatty acid produced by the gut microbiome, have been linked to improved GLP-1 release and satiety.
Prob Integrating Central and Peripheral GLP-1
The authors of this review integrate contributions of both central and peripheral GLP-1, which is secreted from the intestine in response to nutrient ingestion, in a single mechanism of action. Central GLP-1RAs modulate brain regions controlling appetite, while peripheral GLP-1RAs improve glycemic control by enhancing insulin secretion, reducing glucagon levels, and regulating gut hormones. Peripherally, GLP-1RAs have been shown to improve metabolic function, including mitochondrial biogenesis in skeletal muscle, and reduce oxidative stress.
Future Directions for GLP-1 and Iris Function Research
The identification of new actors on the GLP-1 signaling pathway and the exposition of yet unexplored aspects of this mechanism are a flavor of the challenges still to be approached for GLP-1RAs represent only one side of the constantly evolving science area, while the influence of physical activity, hormonal state, cultural background ... (to be continued)
Key Takeaways:
- GLP-1 receptor agonists modulate eating and energy balance through central and peripheral pathways.
- GLP-1 signaling pathways are complex and involve multiple cellular and molecular mechanisms.
- Peripheral GLP-1 serves as an incretin hormone, increasing postprandial insulin secretion and reducing glucagon levels.
- Natural compounds, such as butyrate, can modulate GLP-1 signaling.
- Future directions for GLP-1 and Iris function research include identifying new actors on the GLP-1 signaling pathway and exploring yet unexplored aspects of this mechanism.
